FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
PH1 is an ultra-rare genetic disease characterized by oxalate overproduction. On November 19, the European Commission granted marketing authorization for Oxlumo for the treatment of PH1 in all age groups, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). President of R&D at Alnylam.
52 
Let's personalize your content